Inogen Inc. (NASDAQ:INGN) – Investment analysts at Leerink Swann upped their FY2018 earnings per share (EPS) estimates for shares of Inogen in a report issued on Tuesday. Leerink Swann analyst D. Antalffy now expects that the firm will earn $1.00 per share for the year, up from their previous forecast of $0.95. Leerink Swann currently has a “Outperform” rating and a $60.00 target price on the stock. Leerink Swann also issued estimates for Inogen’s FY2019 earnings at $1.27 EPS and FY2020 earnings at $1.56 EPS.
Inogen (NASDAQ:INGN) last announced its earnings results on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.05. The company earned $54.57 million during the quarter, compared to analysts’ expectations of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.17 earnings per share.
Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Tuesday, August 9th. JPMorgan Chase & Co. upped their price target on shares of Inogen from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Needham & Company LLC restated a “strong-buy” rating and set a $64.00 price target (up previously from $58.00) on shares of Inogen in a research report on Sunday, August 7th. Finally, Stifel Nicolaus lowered shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $55.00.
Shares of Inogen (NASDAQ:INGN) traded down 0.84% during trading on Thursday, reaching $59.00. 129,959 shares of the company’s stock were exchanged. Inogen has a 52 week low of $28.81 and a 52 week high of $61.87. The firm has a market capitalization of $1.19 billion, a PE ratio of 86.76 and a beta of 0.88. The company’s 50-day moving average price is $58.35 and its 200 day moving average price is $50.60.
In related news, EVP Matt Scribner sold 4,551 shares of the stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $60.18, for a total value of $273,879.18. Following the completion of the transaction, the executive vice president now owns 6,884 shares in the company, valued at approximately $414,279.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Raymond Huggenberger sold 20,747 shares of the stock in a transaction dated Monday, July 18th. The shares were sold at an average price of $50.41, for a total transaction of $1,045,856.27. Following the completion of the transaction, the chief executive officer now owns 27,555 shares of the company’s stock, valued at approximately $1,389,047.55. The disclosure for this sale can be found here. 5.18% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in INGN. IFP Advisors Inc raised its position in shares of Inogen by 0.3% in the second quarter. IFP Advisors Inc now owns 2,086 shares of the medical technology company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Springbok Capital Management LLC raised its position in Inogen by 2.5% in the first quarter. Springbok Capital Management LLC now owns 4,100 shares of the medical technology company’s stock valued at $184,000 after buying an additional 100 shares during the period. Arizona State Retirement System raised its position in Inogen by 2.7% in the second quarter. Arizona State Retirement System now owns 7,500 shares of the medical technology company’s stock valued at $376,000 after buying an additional 200 shares during the period. Columbia Asset Management raised its position in Inogen by 0.8% in the second quarter. Columbia Asset Management now owns 29,465 shares of the medical technology company’s stock valued at $1,485,000 after buying an additional 220 shares during the period. Finally, BlackRock Advisors LLC raised its position in Inogen by 6.5% in the second quarter. BlackRock Advisors LLC now owns 7,401 shares of the medical technology company’s stock valued at $371,000 after buying an additional 450 shares during the period.
Inogen Company Profile
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.